Compare SKWD & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKWD | RXRX |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | 800 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2023 | 2021 |
| Metric | SKWD | RXRX |
|---|---|---|
| Price | $47.27 | $4.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $65.30 | $7.25 |
| AVG Volume (30 Days) | 371.1K | ★ 22.9M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.25 | N/A |
| EPS | ★ 3.37 | N/A |
| Revenue | ★ $1,335,358,000.00 | $43,689,000.00 |
| Revenue This Year | $24.41 | $7.79 |
| Revenue Next Year | $30.82 | $27.32 |
| P/E Ratio | $13.92 | ★ N/A |
| Revenue Growth | ★ 22.27 | N/A |
| 52 Week Low | $41.28 | $3.79 |
| 52 Week High | $65.05 | $12.36 |
| Indicator | SKWD | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 52.08 |
| Support Level | $45.73 | $4.32 |
| Resistance Level | $48.50 | $5.09 |
| Average True Range (ATR) | 1.68 | 0.29 |
| MACD | -0.14 | 0.10 |
| Stochastic Oscillator | 42.77 | 77.35 |
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.